Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer

Administered By

Awarded By

Contributors

Start/End

  • November 12, 2019 - September 29, 2024